bcbs michigan glp 1 Blue Cross Blue Shield of Mass. sees gains after years of GLP-1-related losses INSURANCE ALERT: Blue Cross Blue

doi: 10.1152/ajpendo.1998.275.6.E1055

The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jrgensen has agreed to appear at a Senate hearing next week to defend the pricing of the group's semaglutide-based therapies

No in-person visit is required

For patients using these medications to manage obesity including those who had pre-diabetes, metabolic syndrome, or significant cardiovascular risk that restriction can feel deeply unfair, particularly if the medication was working

Physicians want to know about their patients use of unapproved peptides, just as they want to know about any vitamins or other supplements they take